A1 Refereed original research article in a scientific journal

The protective PLCγ2-P522R variant mitigates Alzheimer’s disease-associated pathologies by enhancing beneficial microglial functions




AuthorsTakalo, Mari; Jeskanen, Heli; Rolova, Taisia; Kervinen, Inka; Hellén, Marianna; Heikkinen, Sami; Koivisto, Hennariikka; Jokivarsi, Kimmo; Müller, Stephan A.; Koivumäki, Esa-Mikko; Mäkinen, Petra; Juopperi, Sini-Pauliina; Willman, Roosa-Maria; Sinisalo, Rosa; Hoffmann, Dorit; Jäntti, Henna; Peitz, Michael; Fließbach, Klaus; Kuulasmaa, Teemu; Natunen, Teemu; Kemppainen, Susanna; Poutiainen, Pekka; Leinonen, Ville; Malm, Tarja; Martiskainen, Henna; Ramirez, Alfredo; Haapasalo, Annakaisa; Lichtenthaler, Stefan F.; Tanila, Heikki; Haass, Christian; Rinne, Juha; Koistinaho, Jari; Hiltunen, Mikko

PublisherSpringer Science and Business Media LLC

Publishing placeLONDON

Publication year2025

JournalJournal of Neuroinflammation

Journal name in sourceJournal of Neuroinflammation

Journal acronymJ NEUROINFLAMM

Article number64

Volume22

Issue1

Number of pages30

eISSN1742-2094

DOIhttps://doi.org/10.1186/s12974-025-03387-6

Web address https://doi.org/10.1186/s12974-025-03387-6

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/491569347


Abstract

Background: Phospholipase C gamma 2, proline 522 to arginine (PLCγ2-P522R) is a protective variant that reduces the risk of Alzheimer's disease (AD). Recently, it was shown to mitigate β-amyloid pathology in a 5XFAD mouse model of AD. Here, we investigated the protective functions of the PLCγ2-P522R variant in a less aggressive APP/PS1 mouse model of AD and assessed the underlying cellular mechanisms using mouse and human microglial models.

Methods: The effects of the protective PLCγ2-P522R variant on microglial activation, AD-associated β-amyloid and neuronal pathologies, and behavioral changes were investigated in PLCγ2-P522R knock-in variant mice crossbred with APP/PS1 mice. Transcriptomic, proteomic, and functional studies were carried out using microglia isolated from mice carrying the PLCγ2-P522R variant. Finally, microglia-like cell models generated from human blood and skin biopsy samples of PLCγ2-P522R variant carriers were employed.

Results: The PLCγ2-P522R variant decreased β-amyloid plaque count and coverage in female APP/PS1 mice. Moreover, the PLCγ2-P522R variant promoted anxiety in these mice. The area of the microglia around β-amyloid plaques was also increased in mice carrying the PLCγ2-P522R variant, while β-amyloid plaque-associated neuronal dystrophy and the levels of certain cytokines, including IL-6 and IL-1β, were reduced. These alterations were revealed through [18F]FEPPA PET imaging and behavioral studies, as well as various cytokine immunoassays, transcriptomic and proteomic analyses, and immunohistochemical analyses using mouse brain tissues. In cultured mouse primary microglia, the PLCγ2-P522R variant reduced the size of lipid droplets. Furthermore, transcriptomic and proteomic analyses revealed that the PLCγ2-P522R variant regulated key targets and pathways involved in lipid metabolism, mitochondrial fatty acid oxidation, and inflammatory/interferon signaling in acutely isolated adult mouse microglia and human monocyte-derived microglia-like cells. Finally, the PLCγ2-P522R variant also increased mitochondrial respiration in human iPSC-derived microglia.

Conclusions: These findings suggest that the PLCγ2-P522R variant exerts protective effects against β-amyloid and neuronal pathologies by increasing microglial responsiveness to β-amyloid plaques in APP/PS1 mice. The changes observed in lipid/fatty acid and mitochondrial metabolism revealed by the omics and metabolic assessments of mouse and human microglial models suggest that the protective effects of the PLCγ2-P522R variant are potentially associated with increased metabolic capacity of microglia.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
This work was supported by the Research Council of Finland, grant numbers 330178 (MT), 338182 (MH), and 355604 (HM), and 337530 and 357910 for Flagship InFLAMES (JR); Sigrid Juselius Foundation (MH, AH, JR); Strategic Neuroscience Funding of the University of Eastern Finland (SH, AH, MH); Strategic Funding of the University of Eastern Finland (MT); Doctoral Programme in Molecular Medicine of the University of Eastern Finland (HJ, IK and RMW); Finnish Governmental Research Grant for Turku University Hospital (JR); Alzheimer’s Association, ADSF-24–1284326-C (VL, TM, MH); JPco-fuND-2 ‘Multinational Research Projects on Personalized Medicine for Neurodegenerative Diseases’, grant numbers 334802 (PMG-AD; MH, JK, SL) and Bundesministerium für Bildung und Forschung Grant No. 01ED2007A (PREADAPT, AR); Biocenter Finland (KJ); Innovative Medicines Initiative 2 Joint Undertaking which receives support from the European Union’s Horizon 2020 research and innovation programme (ADAPTED Grant No. 115975, AR); the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy– ID 390857198, SL, CH); and by the Bundesministerium für Bildung und Forschung grant FKZ161L0214C, ClinspectM (SL).


Last updated on 2025-13-05 at 13:50